All Trials

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Open-label, single-arm study of oral repotrectinib, a next-generation macrocyclic TKI targeting ROS1, ALK, and TRK (NTRK1/2/3) with CNS penetration, in children <12 with ALK/ROS1/NTRK-altered advanced malignancies (dose-finding) and adolescents/young adults (12–25) with NTRK fusion–positive (TKI-naïve or pretreated) or ROS1-altered advanced solid tumors/ALCL. Eligible patients require measurable disease and prior progression/intolerance or lack of standard therapy; endpoints include safety/PK in pediatrics and confirmed ORR by BICR in expansion cohorts.

ClinicalTrials.gov ID: NCT04094610

TAGGED: A Phase 2 Study Using Low Dose/Metronomic Trabectedin, Gemcitabine, and Dacarbazine as 2nd/3rd/4th Line Therapy for Advanced Soft Tissue Sarcoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated, locally advanced or metastatic leiomyosarcoma receive a metronomic regimen of trabectedin (DNA minor-groove binder affecting transcription/repair), gemcitabine (nucleoside analog), and dacarbazine (alkylating agent) on Days 1 and 8 of 21-day cycles. Single-arm study aims to assess disease control and tolerability as later-line therapy, treating until progression or toxicity for up to 1 year.

ClinicalTrials.gov ID: NCT04535271

Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolls children and young adults (3–35 years) with refractory/recurrent solid tumors (including CNS tumors, NF1-associated plexiform neurofibromas/MPNST, TGCT) or refractory AML/ALL to receive oral pexidartinib daily in 28-day cycles. Pexidartinib is a small-molecule inhibitor of CSF1R (with KIT and FLT3 activity) targeting tumor-associated macrophages and relevant oncogenic kinases.

ClinicalTrials.gov ID: NCT02390752

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory aggressive B‑cell lymphomas (DLBCL, high‑grade B‑cell lymphoma, PMBCL, transformed FL/FL3B) after prior anti‑CD20/anthracycline therapy—including those previously treated with CD19‑directed therapy or autologous CAR‑T—receive a single infusion of P‑CD19CD20‑ALLO1 after cyclophosphamide/fludarabine lymphodepletion. P‑CD19CD20‑ALLO1 is an off‑the‑shelf allogeneic dual‑target (CD19/CD20) CAR‑T engineered to reduce alloreactivity and HLA‑I expression with an inducible rimiducid safety switch.

ClinicalTrials.gov ID: NCT06014762

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic prostate adenocarcinoma (ECOG 0–1) post–second-generation AR therapy and typically post-taxane (or ineligible/refusing), with PARP inhibitor exposure if BRCA1/2-mutated, receive oral RO7656594 (GDC-2992), a heterobifunctional androgen receptor antagonist/degrader via cereblon-mediated proteasomal degradation. Dose escalation and expansion assess safety, PK, and preliminary activity, excluding prior AR degrader exposure and untreated CNS disease.

ClinicalTrials.gov ID: NCT05800665

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with metastatic rare genitourinary cancers across multiple histologic cohorts (e.g., small cell/neuroendocrine bladder, variant urothelial, penile, sarcomatoid/unclassified RCC, collecting duct, renal medullary, urethral; including a bone-only GU cohort), with up to two prior lines allowed (cohort-specific exceptions. Patients receive cabozantinib (MET/VEGFR2/AXL multi-kinase inhibitor) plus nivolumab (PD-1) and ipilimumab (CTLA-4) for up to 2 years.

ClinicalTrials.gov ID: NCT03866382

A Phase I Clinical Trial of an Infusion of Autologous Gamma Delta T Cells Genetically Engineered With a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients With Metastatic Castration Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Men with metastatic castration‑resistant prostate cancer predominantly to bone, previously treated with at least one taxane (or other chemotherapy) and one AR‑targeted agent, receive lymphodepletion (fludarabine/cyclophosphamide) followed by a single infusion of autologous γδ T cells engineered with a PSCA‑targeted CAR (CD28/CD3ζ), with protocol‑directed zoledronic acid to support γδ T‑cell activation and bone health. Single‑center, open‑label dose escalation/expansion; key exclusions include active viral infections, significant cardiac/autoimmune disease, unstable CNS metastases, and contraindication to zoledronic acid.

ClinicalTrials.gov ID: NCT06193486

An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Men with PSMA-positive metastatic castration-resistant prostate cancer: Phase 1 enrolls post-NAAD and after 1–2 taxane lines; Phase 2 enrolls post-NAAD without prior mCRPC taxanes. Investigational therapy is 177Lu-rhPSMA-10.1, a PSMA-targeted beta-emitting radioligand delivering lutetium-177 to tumor cells, given in various fixed-activity dosing regimens to define safety, dosimetry, and PSA response.

ClinicalTrials.gov ID: NCT05413850

An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic renal cell carcinoma, urothelial carcinoma, or castration-resistant prostate cancer receive oral DCC-2812 monotherapy, a first-in-human, selective GCN2 activator that engages the integrated stress response (eIF2α phosphorylation/ATF4) to disrupt tumor survival pathways. Dose-escalation evaluates safety, dose-limiting toxicities, and PK, with preliminary antitumor activity assessed.

ClinicalTrials.gov ID: NCT06966024

Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with PSMA-avid metastatic castration-resistant prostate adenocarcinoma after prior AR-targeted therapy and taxane chemotherapy receive short-course abemaciclib (CDK4/6 inhibitor) lead-in to upregulate PSMA followed by 177Lu-PSMA-617 radioligand therapy, repeated every 6 weeks for up to 4 cycles. Key eligibility includes ECOG 0–2, maintained castrate testosterone, and no prior CDK4/6 inhibitors or PSMA-RLT.

ClinicalTrials.gov ID: NCT05113537